How do you grade patient care skills when students are training in #VR?

Victoria Huber shares her approach to assessing student performance in #VRNA.

A practical look at how instructors can evaluate competency in virtual training environments.

vrna.net

#VRNA gives students early exposure to healthcare settings and patient care scenarios in a safe, controlled environment where mistakes become learning opportunities instead of stress points.

vrna.net

We love hearing how instructors are using #VRNA day to day. Victoria Huber shares one of the reasons VRNA works so well in CNA programs.

Learn more at vrna.net

📝 CNA instructors and healthcare educators, take notes!

Real classroom insight from Victoria Huber on how she works #VRNA into her lessons and supports students along the way.

Learn more about VRNA at vrna.net

VRSim is proud to support #CTE programs with #SimSpray and #VRNA, which deliver immersive training experiences that prepare students for the demands of the real-world workplace like never before.

vrsim.com

Join us in celebrating #CTEMonth
#CareerTechEd

#VRNA EMS not only enhances your technical skills but also builds your confidence in communicating with patients.

With step-by-step guidance, it prepares you to professionally manage complex interactions and ensure better outcomes in the field.

vrna.net

VRNA provides instructors with a clearer picture of their students' progress.

In this clip, Victoria Huber explains how she uses #VRNA to guide students in real time. She can see who’s on track, who needs extra support, and where to provide more focused instruction.

vrna.net

That’s a wrap on ACTE CareerTech Vision!

We loved visiting with so many instructors and CTE administrators who were excited to learn about #SimSpray and #VRNA.

The positive feedback we received about VRNA AEMS makes us even more excited about its upcoming release next year.

#VISIONCTE25 #CTE

We're heading to Nashville! Join us December 10-11 at ACTE CareerTech Vision (Booth #822) to experience SimSpray, VRNA #CNA, and VRNA #EMS in action. You'll also get an exclusive look at #VRNA AEMS before it launches in early 2026.

#VISIONCTE25

We often hear what instructors think about #VRtraining.
But what about the trainees who are actually wearing the headsets?

Here’s a quick look at what it's like to train with #SimSpray and #VRNA, straight from the trainee and the instructor guiding the journey.

vrsim.com

Our COO, David leading a #VRNA workshop, with instructor Victoria Huber sharing firsthand how VRNA has helped her students build confidence and skills more quickly. A great example of technology making a real difference in training.

“CareerTech Call of Duty” in action!

Franklin County Career and Technology Center’s Allied Health students are putting #VRNA to work, practicing real CNA skills in virtual reality (Crocs encouraged) 😃

Photo credit: Franklin County Career & Technology Center

When we developed #VRNA AEMS, we knew real-life emergencies are loud, chaotic, and high-pressure, so we built those stressors into the simulation.

Pressure is part of the job, so training should prepare you for it.

vrna.net

#VRNA lets students run through critical emergency scenarios that just don't happen in regular classrooms, and you can see it click for them. Chris says it best: they're not just more engaged, they're actually better prepared.

Learn more at vrna.net

October 2025 Transforming EMS Education Through Collaboration and Technology Since 2024, VRSim has partnered with the National Association of Emergency Medical Technicians (NAEMT) to strengthen training and suppor...

October Newsletter is Here!
Big month for us! We showed off #VRNA Advanced EMS at the EMS & FIRE PRO Expo and have some exciting updates on how we're supporting frontline training with immersive technology.

Check it out on our LinkedIn: www.linkedin.com/pulse/octobe...

Merck Completes Acquisition of Verona Pharma Merck, known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc acquisition. The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease in adult patients. Additional Transaction Details Under the terms of the acquisition...

#MRK #VRNA Merck Completes Acquisition of Verona Pharma

www.stocktitan.net/news/MRK/merck-completes...

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &

#VRNA Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

www.stocktitan.net/news/VRNA/acquisition-of...

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck Verona Pharma (NASDAQ: VRNA) shareholders have approved the company's proposed $10 billion acquisition by Merck (NYSE: MRK). The transaction, announced on July 8, 2025, values Verona at $107 per American Depositary Share (ADS), with each ADS representing eight ordinary shares.The acquisition, structured as a scheme of arrangement under English law, received overwhelming shareholder support with 99.49% approval at the Court Meeting and 99.51% approval at the General Meeting. The transaction is expected to close on October 7, 2025, subject to final Court sanction at a hearing scheduled for October 6, 2025.

#VRNA Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

www.stocktitan.net/news/VRNA/shareholders-o...

Are you heading to the EMS & FIRE PRO Expo 2025?

Stop by Booth 221 and see #VRNA EMS in action. Plus, don't miss the unveiling of our BRAND NEW product on Saturday!

Sept 24–27 at Mohegan Sun

Exhibit Hall access is free with registration:
www.emsproexpo.org/event/170939...

We’re heading to EMS & FIRE PRO Expo 2025 at Mohegan Sun from September 24 to 27!

We'll be at Booth 221 showing off #VRNA EMS, our VR training system built specifically for #EMS professionals.

Learn more about the event: www.emsproexpo.org/event/170939...

Victoria Huber, a Nurse Aide Instructor, shares why VR-based tools like #VRNA bring something different to the table, giving students a chance to practice in dynamic, lifelike scenarios that go beyond mere task repetition.

vrna.net

#VRNA is bridging the gap between theoretical knowledge and hands-on experience, making medical education more accessible, effective, and safe for everyone involved.

Learn more at www.vrna.net

VRNA uses a fully immersive #VR experience to increase the effectiveness and reduce the cost of teaching #CNA and #EMS skills.

#VRNA complements lab instruction, helps reduce the material and preparation burden on instructors, and keeps students engaged in lab content.

#MRK #VRNA #060ed581-00a1-4187-8e05-1fad1f71750f #investing

Origin | Interest | Match

Why Verona Pharma’s FDA Win Could Trigger a Billion-Dollar Buyout from a Giant Like Merck "A financial analysis of why Verona Pharma (VRNA) has become a prime acquisition target after its landmark FDA drug approval, and what a deal could mean."

One Year After FDA Approval, Is Verona Pharma the Next Big Pharma Acquisition?

#VeronaPharma #VRNA #Merck #Biotech #FDA #COPD #StockMarket #FactRage #FactRageNews

tglm.us/V3gtG

VRNA 8 Jul 2025 - Trend trading Verona Pharma (VRNA) | Equity Analysis Infographic Verona Pharma plc A New Era in Respiratory Treatment An infographic analysis of the biopharmaceutical company following the landmark FDA approval of its COPD drug, Ohtuvayre®, and its transition to a commercial-stage entity. Market Capitalization $7.7B+ A significant valuation reflecting investor optimism following a major regulatory milestone. Key […]

With reports of a potential $10 billion buyout by Merck, the question for $VRNA isn't if it will move, but how. Forget the noise; the trend is what pays. I'm breaking down the key chart levels to watch.

#VRNA

VRNA 8 Jul 2025 Verona Pharma (VRNA) | Equity Analysis Infographic # Verona Pharma plc A New Era in Respiratory Treatment An infographic analysis of the biopharmaceutical company following the landmark FDA approval of its COPD drug, Ohtuvayre®, and its transition to a commercial-stage entity. Market Capitalization $7.7B+ A significant valuation reflecting investor optimism following a major regulatory milestone. Key Catalyst FDA Approval Ohtuvayre® (ensifentrine) approved in June 2024 for the maintenance treatment of COPD. Analyst Consensus Strong Buy Overwhelmingly positive sentiment from Wall Street, with significant price target upside. ## Technical Analysis: A Powerful Breakout ### Price Trend Analysis VRNA has been in a powerful uptrend, which accelerated dramatically upon FDA approval. The stock is trading at all-time highs, well above its key moving averages, indicating strong bullish control. ### Momentum & Oscillators Momentum indicators are firmly bullish. The MACD is positive and expanding, while the RSI is in overbought territory, reflecting the intense buying pressure following the positive news catalyst. MACD Strongly Positive Bullish Breakout RSI (14-Day) 76.5 Overbought ### Key Price Levels The stock is in price discovery mode. The prior resistance level before the approval news now serves as a key area of technical support. Resistance: All-Time Highs Primary Support: $80.00 – $85.00 50-Day SMA: $79.97 ## Fundamentals: The Transition to Commercialization ### The Path to Revenue Verona has been a pre-revenue company, investing in R&D. The recent FDA approval marks the critical inflection point where the company will begin generating product revenue and transition to a commercial entity. ### Market Opportunity: COPD The target market for Ohtuvayre® is significant. Chronic Obstructive Pulmonary Disease (COPD) is a multi-billion dollar market with a high unmet need for new, effective maintenance therapies. ## The Biotech Commercialization Model Verona Pharma’s model is focused on the discovery, development, and now commercialization of novel therapies for respiratory diseases. 🔬 #### 1. Discover & Develop Identified and developed ensifentrine, a first-in-class inhaled therapy with a dual mechanism of action (bronchodilator and anti-inflammatory). ✅ #### 2. De-Risk via Trials Successfully navigated Phase 3 clinical trials (the ENHANCE studies), proving the drug’s safety and efficacy for COPD treatment. 🚀 #### 3. Commercial Launch Building out a U.S. sales force and marketing strategy to launch Ohtuvayre® and capture a significant share of the COPD market. ## Thesis Summary & Verdict ### Key Bullish Arguments * FDA Approval Secured: The primary de-risking event is complete; Ohtuvayre® is approved for sale in the U.S. * Blockbuster Potential: Targets the massive, multi-billion dollar COPD market with a novel mechanism. * Strong Analyst Support: Unanimous “Buy” ratings from Wall Street with significant price targets. * Pipeline Expansion: Potential to expand ensifentrine’s use into other respiratory diseases like asthma and cystic fibrosis. ### Counter-Arguments & Risks * Commercial Launch Risk: Must now successfully execute a complex and expensive drug launch. * Competition: The respiratory market is dominated by large, established pharmaceutical companies. * Valuation: The stock has already run up significantly on the approval news, pricing in much of the success. * Cash Burn: Will continue to burn cash as it builds its commercial infrastructure before revenue ramps up. Analyst Verdict COMMERCIAL-STAGE GROWTH Verona Pharma has successfully crossed the chasm from a development-stage to a commercial-stage company. The investment thesis now shifts from clinical risk to execution risk. Given the blockbuster potential of Ohtuvayre®, VRNA is a compelling growth story for investors with a tolerance for biotech volatility. Confidence: Medium | Timeframe: 2-4 Years ### Share this: * Click to share on Facebook (Opens in new window) Facebook * Click to share on X (Opens in new window) X * ### Like this: Like Loading... ### _Related_

With reports of a potential $10 billion buyout by Merck, the question for $VRNA isn't if it will move, but how. Forget the noise; the trend is what pays. I'm breaking down the key chart levels to watch.

#VRNA
https://overwi.se/2025/07/09/vrna-8-jul-2025/

At VRSim, this belief shapes everything we build.

From #SimSpray to #VRNA, our #VR training tools are built for how students learn today: through hands-on experience, instant feedback, and immersive environments that keep them engaged.

www.vrsim.com

Interested in learning more about #VRNA? Watch this video to check out our latest FAQ. Have more questions?

Drop them in the comments and we'll be happy to answer!